KLOW (GHK-Cu 50 mg + BPC-157 10 mg + TB-500 10 mg + KPV 10 mg)

Protocol Overview

Concise summary of the regimen.

Dosing & Reconstitution

Frequency: Inject once daily subcutaneously. This schedule follows a conservative titration to assess individual response. For 10 unit (0.10 mL) or smaller administrations, consider 30- or 50-unit insulin syringes for improved readability.

Reconstitution Steps

1. Draw 3 mL bacteriostatic water with a sterile syringe.
2. Inject slowly down the vial wall to minimize foaming.
3. Gently swirl or roll the vial until fully dissolved (do not shake vigorously).
4. Label with reconstitution date and refrigerate at 2 to 8 °C, protected from light.
5. Use within 4 weeks for optimal potency and safety. Syringe math: at ~26.67 mg/mL total, TB-500, BPC-157, and KPV are each at 3.33 mg/mL (33.3 mcg per unit) and GHK-Cu at 16.67 mg/mL (166.7 mcg per unit); 1 unit = 0.01 mL » 33.3 mcg each of TB-500, BPC-157, KPV + 166.7 mcg GHK-Cu on a U-100 insulin syringe.

Storage Instructions

Proper storage preserves peptide quality.

• Lyophilized: store at -20 °C or below for long-term stability (months to over a year). If freezer unavailable,

refrigeration at 2 to 8 °C is acceptable for shorter durations.

• Reconstituted: refrigerate at 2 to 8 °C at all times when not in use; do not freeze reconstituted solution;

use within 4 weeks (28 days).

• Allow frozen vials to reach room temperature before opening to prevent condensation.
• Protect reconstituted solution from light; inspect before each use and discard if discolored, cloudy, or

contains precipitate.

Supplies Needed

Plan based on an 8 to 16 week daily protocol with gradual titration.

Peptide Vials (KLOW, 80 mg each):

• 8 weeks: ~3 vials. 12 weeks: ~4 vials. 16 weeks: ~5 vials.

Insulin Syringes (U-100, preferably 0.3 mL / 30-unit for precision):

• Per week: 7 syringes (1 per day). 8 weeks: 56. 12 weeks: 84. 16 weeks: 112.

Bacteriostatic Water (10 mL bottles):

• 8 weeks (3 vials): 1 bottle. 12 weeks (4 vials): 2 bottles. 16 weeks (5 vials): 2 bottles.

Alcohol Swabs:

• Per week: 14 swabs. 8 weeks: 112 (2 x 100-count). 16 weeks: 224 (3 x 100-count).

Important Notes

Practical considerations for consistency and safety.

• Use new sterile insulin syringes for each injection; dispose in a sharps container immediately after use.
• Rotate injection sites systematically (abdomen, thighs, upper arms) at least 1 to 2 inches apart.
• Inject slowly over 2 to 3 seconds and wait a few seconds before withdrawing the needle.
• Document daily dose, injection site, and any observations to maintain consistency and track progress.
• Practice aseptic technique at every injection: clean vial stopper and skin with separate alcohol swabs,

allow to air-dry completely.

How This Works

Mechanisms of action.

KLOW combines four peptides with complementary mechanisms of action. TB-500 (Thymosin Beta-4) promotes angiogenesis, cell migration, and tissue repair by regulating actin. BPC-157 is a gastric pentadecapeptide that supports tendon, ligament, and muscle healing through enhanced angiogenesis and growth factor modulation. KPV is a C-terminal tripeptide fragment of a-MSH with potent anti-inflammatory properties: it inhibits NF-kB signaling and reduces pro-inflammatory cytokines without melanotropic effects. GHK-Cu is a naturally occurring copper peptide that stimulates collagen and elastin synthesis, promotes wound healing, and modulates gene expression related to tissue remodeling.

Benefits & Side Effects

Observations from preclinical and early-stage research.

• Accelerated tissue repair and wound healing through multiple complementary pathways.
• Reduced inflammation via NF-kB inhibition and cytokine modulation.
• Enhanced collagen synthesis and connective tissue support.
• Promotion of angiogenesis and improved blood flow to healing tissues.
• Potential support for musculoskeletal recovery and joint health.
• Mild injection-site reactions (redness, irritation) may occur with subcutaneous administration.
• Occasional lightheadedness reported with some peptides due to vasodilatory effects.
• Limited human clinical data; most safety observations derive from preclinical studies.

Lifestyle Factors

Complementary strategies for best outcomes.

• Maintain adequate protein intake (1.6 to 2.2 g/kg body weight daily) to support collagen synthesis and

tissue repair.

• Implement progressive resistance training and appropriate activity modification based on healing goals.
• Prioritize sleep quality (7 to 9 hours nightly) as the primary recovery window for tissue regeneration.
• Manage stress through evidence-based techniques to support an optimal healing hormonal environment.
• Stay well-hydrated and ensure adequate micronutrient intake, particularly vitamin C, zinc, and copper.

Injection Technique

General subcutaneous guidance from clinical best-practice resources.

1. Clean the vial stopper and skin with alcohol; allow to dry.
2. Pinch a skinfold; insert the needle at 45 to 90 degrees into subcutaneous tissue.
3. Do not aspirate for subcutaneous injections; inject slowly and steadily.
4. Wait 5 to 10 seconds before withdrawing; dispose of syringe in sharps container.
5. Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy.

References

Source citations for further reading.

1. Philp D et al. Thymosin beta 4 accelerates wound healing (1999).
2. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review (HSS Journal, 2025).
3. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation (Gastroenterology).
4. Pickart L. Regenerative and Protective Actions of the GHK-Cu Peptide in Light of New Gene Data (Int J Mol Sci, 2018).